Abstract 137P
Background
Recent single-cell DNA sequencing (scDNA-seq) technologies have enabled the parallel investigation of thousands of individual cells. This is required for accurately reconstructing tumour evolution, during which cancer cells acquire a multitude of different genetic alterations. Although the evolutionary analysis of scDNA-seq datasets is complex due to their unique combination of errors and missing data, several methods have been developed to infer single-cell tumour phylogenies by integrating estimates of the false positive and false negative error rates. This integration relies on the assumption that errors are uniformly distributed both within and across cells. However, this assumption does not always hold; error rates depend on sequencing coverage, which is not constant within or across cells in a sequencing experiment due to, e.g., copy-number alterations and the replication status of a cell, limiting the accuracy of existing methods.
Methods
To address this challenge, we developed PHANTOM, a novel single-cell phylogenetic method that integrates raw sequencing read counts into a statistical framework to robustly correct the errors and missing data. PHANTOM includes bootstrapping to correct for high error frequency genomic positions and a fast probabilistic heuristic based on hypothesis testing to distinguish the remaining errors from truly observed genotypes.
Results
We demonstrate the improved accuracy and robustness of our method compared to existing approaches across several simulation settings. To demonstrate its impact, we applied our method to scDNA-seq datasets comprising >25,000 cells from 31 patients with triple-negative breast cancer or high-grade serous ovarian cancer, as well as targeted scDNA-seq from a cohort of 123 patients with acute myeloid leukaemia, revealing more accurate phylogenies consistent with copy-number alterations.
Conclusions
We developed PHANTOM, a novel single-cell phylogenetic method that accurately and robustly infers single-cell tumour phylogenies. We applied PHANTOM to scDNA-seq cancer datasets, revealing its potential to investigate tumour evolution at unprecedented resolution.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Cancer Research UK.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
163TiP - Single-institution, single-arm, open-label phase II basket study of mutation and/or elevated hedgehog (Hh) expression-directed smoothened inhibitor sonidegib in patients with advanced solid malignancies
Presenter: Madhawa De Silva
Session: Cocktail & Poster Display session
Resources:
Abstract
164TiP - MONSTAR-GLYCO: A multi-institutional prospective study harnessing glycomics and multi-omics on the j-glyconet and SCRUM-MONSTR platform
Presenter: Tadayoshi Hashimoto
Session: Cocktail & Poster Display session
Resources:
Abstract
166P - Unravelling HR-positive, HER2-negative breast cancer and its tumor microenvironment heterogeneity using spatial transcriptomics
Presenter: Bengisu Karakose
Session: Cocktail & Poster Display session
Resources:
Abstract
167P - Cancer neutrophil encyclopedia: A deep dive into antigen-presenting warriors
Presenter: Yingcheng Wu
Session: Cocktail & Poster Display session
Resources:
Abstract
168P - Tumor microenvironment (TME) and PD-L1 expression heterogeneity in high grade serous ovarian cancer (HGSC) samples analysis from the randomized NeoPembrOV/GINECO phase II trial
Presenter: Laetitia Collet
Session: Cocktail & Poster Display session
Resources:
Abstract
169P - Tumour microenvironment in glioblastoma: A single-cell perspective on macrophage dynamics and T cell exhaustion
Presenter: Farasat Kazmi
Session: Cocktail & Poster Display session
Resources:
Abstract
170P - Digital spatial profiling to uncover biomarkers for response prediction in locally advanced gastric cancer patients treated with neoadjuvant chemotherapy
Presenter: Chiara Molinari
Session: Cocktail & Poster Display session
Resources:
Abstract
171P - Immune-modulatory drug profiling using perfused, microfluidic on-chip co-cultures of patient-derived ovarian cancer microtumors and autologous immune cells
Presenter: Sarah Plöger
Session: Cocktail & Poster Display session
Resources:
Abstract
172P - The impact of androgen ablation on the immune landscape in therapy-resistant prostate cancer: Insights from tumour microenvironment analysis
Presenter: Jodi Stewart
Session: Cocktail & Poster Display session
Resources:
Abstract
173P - NRF2 levels in high grade serous ovarian cancer: Characterization and treatment
Presenter: Helen Toma
Session: Cocktail & Poster Display session
Resources:
Abstract